Simcere Pharmaceutical’s Edaravone and Borneol Sublingual Tablets Approved for AIS Treatment in China
China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced receiving marketing approval from the National...
Shanghai Pharmaceuticals Concludes Phase II Study for I037 in Acute Ischemic Stroke
Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced the completion of data...
Affinity (Shanghai) Secures Over RMB 400 Million in Series B2 Financing to Advance Oncology Drugs
Affinity (Shanghai), the parent company of Shanghai Affinity Biopharmaceutical Co., Ltd., has reportedly raised upwards...
Abogen Biosciences and Ruijin Hospital Launch Ruijin Abogen Nucleic Acid Drug Research Institute
China-based nucleic acid drug developer Suzhou Abogen Biosciences and Ruijin Hospital, a comprehensive Class 3A...
Henlius Biotech Initiates US Commercial Supply of Hanquyou, Biosimilar to Herceptin
Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the initiation of commercial supply of its...
ImmuneOnco Biopharmaceuticals Receives NMPA Approval for Lupus Nephritis Phase II Study
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced receiving approval from...
Healthgen Biotechnology’s Plant-Made Albumin Breakthrough: A Milestone in Serum Therapy
On November 30th, Healthgen Biotechnology Corp. announced a significant research outcome at the 9th Pharmaceutical...
Shanghai Cell Therapy Group’s Second Attempt at HK IPO Receives Green Light from CICC and CCB International
Shanghai Cell Therapy Group Co., Ltd., a leading player in China’s cellular medical health sector,...
Nanjing Leads Biolabs Commences IPO Process with Focus on Innovative Therapies
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biopharmaceutical company focused on developing innovative therapies for...
XellSmart Bio-Pharmaceutical Achieves Milestone with First Patient Enrollment in Global iPSC Clinical Study for ALS
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd., in collaboration with Shanghai East Hospital (Tongji University Affiliated East...
Cutia Therapeutic’s CU-20401 Shows Positive Results in Phase II Subcutaneous Fat Reduction Study
China-based dermatology specialist Cutia Therapeutic (HKG: 2487) has revealed a positive readout from its Phase...
OBiO Technology Partners with Hanxin Biotechnology to Advance LNP Delivery System
China-based gene therapy Contract Research Organization (CRO) OBiO Technology (Shanghai) Co., Ltd (SHA: 688238) has...
NMPA Approves Shenzhen Mindray’s Innovative Dual-Mode Ultrasound Diagnostic System
The National Medical Products Administration (NMPA) has granted approval to Shenzhen Mindray Bio-Medical Electronics Co.,...
NMPA Approves Hangzhou Ruidi Biotechnology’s Steep Pulse Therapy Equipment for Tumor Treatment
China’s National Medical Products Administration (NMPA) has granted approval to Hangzhou Ruidi Biotechnology Co., Ltd...
CDE Expands Care Plan with Approvals for Ractigen’s RAG-17 and Vitalgen’s VGR-R01
In a swift succession of actions, China’s Center for Drug Evaluation (CDE) has added two...
NMPA Drafts Medical Representative Management Measures, Seeks Public Input
The National Medical Products Administration (NMPA) has released the “Medical Representative Management Measures (draft proposal)”,...
Daiichi Sankyo Invests RMB 1.1 Billion in New ADC Manufacturing Plant in Shanghai
Japanese pharmaceutical company Daiichi Sankyo (TYO: 4568) is significantly increasing its investment in China with...
Jiangsu Kanion Pharmaceutical Gets NMPA Clearance for Oncolytic Virus Product KYS202003A
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced that it has received clinical clearance...
Lingyi Biotechnology and Jolly Pharmaceutical Ink Comprehensive Collaboration Agreement
China-based gene therapy specialist Lingyi Biotechnology Co., Ltd has entered into a comprehensive collaboration agreement...
Sichuan Biokin Pharmaceutical’s BL-M08D1 ADC Receives NMPA Approval for Clinical Trials
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...